Jandl Katharina, Stacher Elvira, Bálint Zoltán, Sturm Eva Maria, Maric Jovana, Peinhaupt Miriam, Luschnig Petra, Aringer Ida, Fauland Alexander, Konya Viktoria, Dahlen Sven-Erik, Wheelock Craig E, Kratky Dagmar, Olschewski Andrea, Marsche Gunther, Schuligoi Rufina, Heinemann Akos
Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria.
Institute of Pathology, Medical University of Graz, Graz, Austria.
J Allergy Clin Immunol. 2016 Mar;137(3):833-43. doi: 10.1016/j.jaci.2015.11.012. Epub 2016 Jan 12.
Prostaglandin (PG) D2 is an early-phase mediator in inflammation, but its action and the roles of the 2 D-type prostanoid receptors (DPs) DP1 and DP2 (also called chemoattractant receptor-homologous molecule expressed on T(H)2 cells) in regulating macrophages have not been elucidated to date.
We investigated the role of PGD2 receptors on primary human macrophages, as well as primary murine lung macrophages, and their ability to influence neutrophil action in vitro and in vivo.
In vitro studies, including migration, Ca(2+) flux, and cytokine secretion, were conducted with primary human monocyte-derived macrophages and neutrophils and freshly isolated murine alveolar and pulmonary interstitial macrophages. In vivo pulmonary inflammation was assessed in male BALB/c mice.
Activation of DP1, DP2, or both receptors on human macrophages induced strong intracellular Ca(2+) flux, cytokine release, and migration of macrophages. In a murine model of LPS-induced pulmonary inflammation, activation of each PGD2 receptor resulted in aggravated airway neutrophilia, tissue myeloperoxidase activity, cytokine contents, and decreased lung compliance. Selective depletion of alveolar macrophages abolished the PGD2-enhanced inflammatory response. Activation of PGD2 receptors on human macrophages enhanced the migratory capacity and prolonged the survival of neutrophils in vitro. In human lung tissue specimens both DP1 and DP2 receptors were located on alveolar macrophages along with hematopoietic PGD synthase, the rate-limiting enzyme of PGD2 synthesis.
For the first time, our results show that PGD2 markedly augments disease activity through its ability to enhance the proinflammatory actions of macrophages and subsequent neutrophil activation.
前列腺素(PG)D2是炎症早期的介质,但其作用以及2种D型前列腺素受体(DPs)DP1和DP2(也称为在辅助性T细胞2(TH2)上表达的趋化因子受体同源分子)在调节巨噬细胞中的作用迄今尚未阐明。
我们研究了PGD2受体在原代人巨噬细胞以及原代小鼠肺巨噬细胞上的作用,及其在体外和体内影响中性粒细胞作用的能力。
使用原代人单核细胞衍生的巨噬细胞和中性粒细胞以及新鲜分离的小鼠肺泡和肺间质巨噬细胞进行了包括迁移、Ca(2+)通量和细胞因子分泌在内的体外研究。在雄性BALB/c小鼠中评估体内肺部炎症。
激活人巨噬细胞上的DP1、DP2或两种受体均诱导强烈的细胞内Ca(2+)通量、细胞因子释放和巨噬细胞迁移。在脂多糖诱导的肺部炎症小鼠模型中,每种PGD2受体的激活均导致气道中性粒细胞增多、组织髓过氧化物酶活性、细胞因子含量加重以及肺顺应性降低。肺泡巨噬细胞的选择性耗竭消除了PGD2增强的炎症反应。激活人巨噬细胞上的PGD2受体可增强体外中性粒细胞的迁移能力并延长其存活时间。在人肺组织标本中,DP1和DP2受体与造血PGD合酶(PGD2合成的限速酶)一起位于肺泡巨噬细胞上。
我们的结果首次表明,PGD2通过增强巨噬细胞的促炎作用和随后的中性粒细胞激活,显著增强疾病活动。